Vincent Ribrag

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Clinical cancer research : an official journal of the American Association for Cancer Research · Mar 2, 2026

Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.

Haematologica · Oct 30, 2025

EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma.

HemaSphere · Oct 1, 2025

Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.

Blood cancer journal · Apr 24, 2025

Mantle cell lymphoma: what clinical progress in the last 5 years?

Expert opinion on investigational drugs · Mar 1, 2025

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.

British journal of haematology · Jan 1, 2025

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.

Blood · Jul 18, 2024

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Leukemia · Jun 1, 2024

Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 1, 2024

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Feb 10, 2024